Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AMAG Pharmaceuticals Inc Raises FY 2013 Revenue Guidance


Thursday, 1 Aug 2013 07:30am EDT 

AMAG Pharmaceuticals Inc updated its annual financial guidance for fiscal 2013. AMAG now expects to achieve the following in fiscal 2013: Total revenues of between $77 million and $80 million, including: Feraheme U.S. net product sales of between $67 million and $70 million, revised upward from the Company's previous estimate of between $63 million and $67 million; Revenues from other sources of approximately $10 million, including ex-U.S. Feraheme/Rienso product sales, royalties and amortization of milestones as well as MuGard product sales. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $76 million for fiscal 2013. 

Company Quote

20.03
0.06 +0.30%
11 Jul 2014